Trial reportInternational journal of clinical oncology2019
CT-guided percutaneous radiofrequency ablation for lung metastases from colorectal cancer.
Trial report in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Percutaneous Cryoablation Under Local Anesthesia for Pulmonary Metastases From Colorectal Cancer: Long-Term Outcomes From a Single-Institution Retrospective Cohort.Cancer reports (Hoboken, N.J.) · 2026Article
- Habitat-based radiomics analysis for evaluating immediate response in colorectal cancer lung metastases treated by radiofrequency ablation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Contemporary Outcomes for the Curative Treatment of Colorectal Cancer Pulmonary Metastases.Journal of gastrointestinal cancer · 2023Article
- Long-Term Effects of a Ketogenic Diet for Cancer.Nutrients · 2023Article
- Up-to-date evidence on image-guided thermal ablation for metastatic lung tumors: a review.Japanese journal of radiology · 2022Review
- Long-term outcome following microwave ablation of lung metastases from colorectal cancer.Frontiers in oncology · 2022Article
- Image-guided percutaneous ablation for lung malignancies.Frontiers in oncology · 2022Review
- Advances and controversies in the management of early stage non-small cell lung cancer.World journal of clinical oncology · 2021Review
- Radiomics complements clinical, radiological, and technical features to assess local control of colorectal cancer lung metastases treated with radiofrequency ablation.European radiology · 2021Article
- Role of surgical resection and its alternative local therapy for pulmonary metastasis of colorectal cancer.Annals of gastroenterological surgery · 2021Review
- Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation.Thoracic cancer · 2021Article
- Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.BMC cancer · 2021Article
- Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art.Insights into imaging · 2021Review
- Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- CT-Guided Percutaneous Cryoablation for Lung Metastasis of Colorectal Cancer: A Case Series.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiofrequency ablation (RFA) can be a minimally invasive therapeutic option in patients with lung metastasis from colorectal caner. We aimed to elucidate the safety and survival benefit of computed tomography (CT)-guided percutaneous RFA for lung metastasis from colorectal cancer.
methodsA total 188 lesions were ablated in 43 patients from 2005 to 2017. The clinicopathological and survival data of patients were collected retrospectively. The short- and long-term outcomes and prognostic factors were analyzed.
resultsEight patients (18.6%) had viable extrapulmonary metastasis at RFA treatment. The median number of treated lung tumors was 2, and the median maximum diameter was 12 mm. Complications, such as pneumothorax, pleural effusion and subcutaneous emphysema, occurred in 24 (55.8%) patients. Although chest tube drainage for pneumothorax was needed in 6 patients (14.0%), there were no mortalities. Repeated RFA for lung recurrence after primary RFA was performed in 14 patients (32.6%). In a median follow-up of 24.3 months, the median progression-free and overall survival (OS) were 6.8 months and 52.7 months, respectively. The presence of extrapulmonary metastasis and a maximum tumors size of > 15 mm were independently associated with a worse disease-free survival and OS. The OS of patients who underwent repeated RFA was significantly better than that of patients who underwent RFA only once.
conclusionCT-guided percutaneous RFA for lung metastasis from colorectal cancer is a safe and effective procedure in patients not eligible for surgery, particularly for lesions smaller than 1.5 cm without extrapulmonary metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.